

Ketty Peris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4902811/publications.pdf>

Version: 2024-02-01

183
papers

4,990
citations

126858

33
h-index

133188

59
g-index

187
all docs

187
docs citations

187
times ranked

5655
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	1.3	345
2	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	1.3	330
3	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. <i>British Journal of Dermatology</i> , 2021, 184, 437-449.	1.4	289
4	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	1.3	181
5	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	1.3	154
6	Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. , 2017, 8, 643.		146
7	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	9.4	138
8	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	1.3	133
9	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	1.3	131
10	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). <i>European Journal of Cancer</i> , 2019, 114, 117-127.	1.3	120
11	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	1.3	102
12	Evidence for a “window of opportunity”™ in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study*. <i>British Journal of Dermatology</i> , 2021, 184, 133-140.	1.4	88
13	Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. <i>Journal of Dermatological Treatment</i> , 2017, 28, 431-442.	1.1	76
14	Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 507-513.	1.1	67
15	Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 958-964.	1.3	66
16	Pruritus as a Distinctive Feature of Type 2 Inflammation. <i>Vaccines</i> , 2021, 9, 303.	2.1	66
17	Dietary compounds as potential modulators of microRNA expression in psoriasis. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231986480.	1.1	63
18	The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1356-1363.	0.6	61

#	ARTICLE	IF	CITATIONS
19	Conventional vs. daylight methyl aminolevulinic acid photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1926-1932.	1.3	59
20	Treatment of severe psoriasis in children: recommendations of an Italian expert group. <i>European Journal of Pediatrics</i> , 2017, 176, 1339-1354.	1.3	58
21	Defining the actinic keratosis field: a literature review and discussion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 544-563.	1.3	54
22	Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1732-1741.	1.3	53
23	Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 727-735.	1.4	52
24	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	1.3	52
25	Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 39-45.	0.6	51
26	Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 665-672.	1.4	49
27	Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1310-1320.	0.6	48
28	Italian expert consensus for the management of actinic keratosis in immunocompetent patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1077-1084.	1.3	41
29	Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. <i>Journal of Hepatology</i> , 2019, 71, 366-370.	1.8	41
30	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE AD7 Phase 3 randomized trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1543-1552.	1.3	41
31	Drug-induced hair colour changes. <i>European Journal of Dermatology</i> , 2016, 26, 531-536.	0.3	37
32	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018, 104, 201-209.	1.3	37
33	Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy. <i>Journal of Dermatological Treatment</i> , 2016, 27, 443-447.	1.1	36
34	European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force "Dermatology for cancer patients" position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 332-350.	1.3	36
35	Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. <i>Future Oncology</i> , 2015, 11, 703-712.	1.1	35
36	Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. <i>Human Molecular Genetics</i> , 2018, 27, 4145-4156.	1.4	34

#	ARTICLE	IF	CITATIONS
37	Prevalence and determinants of sunbed use in thirty European countries: data from the Euromelanoma skin cancer prevention campaign. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 13-27.	1.3	34
38	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021, 11, 235-252.	1.4	34
39	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 932-941.	1.3	33
40	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	0.8	33
41	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. <i>European Journal of Cancer</i> , 2017, 75, 313-322.	1.3	32
42	Untreated Psoriasis Impairs Male Fertility: A Case-Control Study. <i>Dermatology</i> , 2017, 233, 170-174.	0.9	32
43	A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e169-e170.	1.3	31
44	Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. <i>European Journal of Dermatology</i> , 2017, 27, 599-608.	0.3	30
45	Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases*. <i>British Journal of Dermatology</i> , 2022, 186, 925-941.	1.4	29
46	Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. <i>International Journal of Dermatology</i> , 2016, 55, e289-94.	0.5	28
47	Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. <i>PLoS ONE</i> , 2017, 12, e0183415.	1.1	27
48	Photodynamic therapy for basal cell carcinoma. <i>Future Oncology</i> , 2015, 11, 2991-2996.	1.1	25
49	Treatments of actinic cheilitis: A systematic review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 876-887.	0.6	25
50	Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis. <i>Dermatology</i> , 2018, 234, 66-70.	0.9	24
51	Physician perceptions and experience of current treatment in actinic keratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 298-306.	1.3	23
52	Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1292-1299.	1.3	23
53	Basal cell carcinoma: the utility of <i>in vivo</i> and <i>ex vivo</i> confocal microscopy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2090-2096.	1.3	22
54	Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 110-122.	1.2	22

#	ARTICLE	IF	CITATIONS
55	Cutaneous squamous cell carcinoma. Italian Guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 747-762.	0.8	22
56	A case of guttate psoriasis during treatment with dupilumab. <i>Dermatologic Therapy</i> , 2019, 32, e12998.	0.8	22
57	The evolving field of Dermatocancerology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV and UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	1.3	22
58	Clinical predictors of nonresponse to anti-TNF agents in psoriatic patients: A retrospective study. <i>Dermatologic Therapy</i> , 2016, 29, 372-376.	0.8	21
59	Childhood trauma and resilience in psoriatic patients: A preliminary report. <i>Journal of Psychosomatic Research</i> , 2018, 106, 25-28.	1.2	21
60	A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. <i>European Journal of Dermatology</i> , 2018, 28, 162-168.	0.3	19
61	Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 956-966.	1.3	19
62	A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1146-1149.	1.1	19
63	Molecular alterations in basal cell carcinoma subtypes. <i>Scientific Reports</i> , 2021, 11, 13206.	1.6	19
64	Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1299-1310.	1.4	19
65	Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia. <i>Genetics in Medicine</i> , 2021, 23, 2087-2095.	1.1	19
66	A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2192-2198.	1.3	18
67	Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports. <i>Journal of International Medical Research</i> , 2016, 44, 67-71.	0.4	18
68	Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. <i>Dermatology</i> , 2021, 237, 535-541.	0.9	18
69	A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 339-352.	3.3	18
70	Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 8005.	1.6	17
71	Paradigmatic cases of pigmented lesions: How to not miss melanoma. <i>Journal of Dermatology</i> , 2016, 43, 1433-1437.	0.6	16
72	Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 299-303.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Psoriasis Area and Severity Index response in moderate-to-severe psoriatic patients switched to adalimumab: results from the <scp>OPPSA</scp> study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1737-1744.	1.3	16
74	Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (<scp>AK</scp>-<scp>TRAIN</scp>): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 93-107.	1.3	16
75	The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. Radiologia Medica, 2022, 127, 773-783.	4.7	16
76	Role of personalized medication training in improving efficacy and adherence to a topical therapy in psoriatic patients. Journal of Dermatological Treatment, 2017, 28, 722-725.	1.1	15
77	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 515-528.	1.3	15
78	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. Genome Medicine, 2018, 10, 99.	3.6	15
79	Association of sunbed use with skin cancer risk factors in Europe: an investigation within the Euromelanoma skin cancer prevention campaign. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 76-88.	1.3	15
80	Adherence to topical therapies in actinic keratosis: A literature review. Journal of Dermatological Treatment, 2016, 27, 538-545.	1.1	14
81	Post-bariatric surgery hidradenitis suppurativa: a new patient subset associated with malabsorption and micronutritional deficiencies. Clinical and Experimental Dermatology, 2019, 44, 283-289.	0.6	14
82	Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e427-e428.	1.3	14
83	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2149-2153.	1.3	14
84	Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2160-2168.	1.3	13
85	Rationale for the Development of Speckled Hyperpigmentation in the Areas of Psoriatic Plaques after Treatment with Biologic Agents. Journal of Investigative Dermatology, 2015, 135, 318-320.	0.3	13
86	Cutaneous melanoma in Birt-Hogg-Dubois syndrome: part of the clinical spectrum?. British Journal of Dermatology, 2018, 178, e132-e133.	1.4	13
87	Alexithymia affects patients with hidradenitis suppurativa. European Journal of Dermatology, 2018, 28, 482-487.	0.3	13
88	Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2019, 20, 1333.	1.8	13
89	Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. Dermatologic Therapy, 2022, 35, e15489.	0.8	13
90	Melanoma and tattoos: a case report and review of the literature. European Journal of Dermatology, 2018, 28, 50-55.	0.3	13

#	ARTICLE	IF	CITATIONS
91	Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 320-321.	1.3	12
92	Long-term efficacy and safety of daylight photodynamic therapy with methyl aminolevulinate for actinic keratosis of the face and scalp. <i>European Journal of Dermatology</i> , 2017, 27, 89-91.	0.3	12
93	Italian expert consensus paper on the management of patients with actinic keratoses. <i>Dermatologic Therapy</i> , 2020, 33, e13992.	0.8	12
94	Frailty screening in dermatology practice: a modified Delphi study and a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 95-104.	1.3	12
95	Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 279-286.	1.4	12
96	A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	12
97	Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 525-530.	1.1	11
98	Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa. <i>JAMA Dermatology</i> , 2020, 156, 708.	2.0	11
99	Non-Melanoma Skin Cancer in Outdoor Workers: A Study on Actinic Keratosis in Italian Navy Personnel. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2321.	1.2	11
100	Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2470-2473.	1.3	10
101	Imiquimod 3.75% in actinic keratosis: efficacy in patients with and without rest periods during treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1416-1417.	1.3	10
102	Linagliptin-induced bullous pemphigoid. <i>International Journal of Dermatology</i> , 2017, 56, 1467-1469.	0.5	10
103	Sunbed use legislation in Europe: assessment of current status. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 89-96.	1.3	10
104	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1949-1956.	1.3	10
105	Treatment approaches of advanced cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 19-22.	1.3	10
106	Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 347-355.	1.5	10
107	Brown globules in lentigo maligna (LM): A useful dermoscopic clue. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 429-430.	0.6	9
108	Dermoscopy of small-size basal cell carcinoma: a case-control study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e273-e274.	1.3	9

#	ARTICLE	IF	CITATIONS
109	MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2134-2141.	1.3	9
110	<p>Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential</p>. <i>Psoriasis: Targets and Therapy</i> , 2019, Volume 9, 29-35.	1.2	9
111	Multiple paradoxical reactions during ixekizumab therapy. <i>Dermatologic Therapy</i> , 2019, 32, e12852.	0.8	9
112	Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. <i>Dermatology</i> , 2020, 236, 329-335.	0.9	9
113	Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. <i>European Journal of Dermatology</i> , 2019, 29, 192-196.	0.3	9
114	Hidradenitis suppurativa and adalimumab in the COVID-19 era. <i>European Journal of Dermatology</i> , 2020, 30, 748-749.	0.3	9
115	<i>Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDEmaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological Occupati.</i> <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 184-197.	0.1	9
116	Conventional Treatment of Actinic Keratosis: An Overview. <i>Current Problems in Dermatology</i> , 2015, 46, 108-114.	0.8	8
117	Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1840-1842.	1.3	8
118	Lichen sclerosus of the glans simulating melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, S49-S51.	0.6	8
119	Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities. <i>Dermatologic Therapy</i> , 2019, 32, e13108.	0.8	8
120	Contribution of Common Genetic Variants to Familial Aggregation of Disease and Implications for Sequencing Studies. <i>PLoS Genetics</i> , 2019, 15, e1008490.	1.5	8
121	Antihypertensive drugs and risk of skin cancer. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 672-684.	0.8	8
122	Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 335-340.	0.8	8
123	New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 411-420.	0.8	8
124	Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. <i>Dermatology</i> , 2022, 238, 717-724.	0.9	8
125	Biological agents targeting interleukin-13 for atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 651-659.	1.4	8
126	Age and gender influence on HIDRADisk outcomes in adalimumab-treated hidradenitis suppurativa patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 25-27.	1.3	7

#	ARTICLE	IF	CITATIONS
127	Sonidegib after vismodegib discontinuation in a patient with Gorlin's syndrome and multiple basal cell carcinomas. <i>Dermatologic Therapy</i> , 2021, 34, e15095.	0.8	7
128	Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 127-134.	0.6	7
129	A rare case of bullous Sweet's syndrome in a patient with inactive ulcerative colitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e380-e381.	1.3	6
130	Likelihood of finding melanoma when removing a melanocytic lesion with peripheral clods. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e812-e814.	1.3	6
131	Recalcitrant Sweet Syndrome successfully treated with adalimumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 122-124.	0.4	6
132	Adverse cutaneous and mucous reactions from anti SARS-CoV-2 vaccines: recommendations from the Italian Society of Dermatology (SIDeMaST). <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 115-117.	0.1	6
133	A familial case of Dowling-Degos disease on the vulva. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 921-923.	0.6	5
134	Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e342-e344.	1.3	5
135	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1119-1132.	1.3	5
136	Skin rashes and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-8.	1.4	5
137	Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to-severe psoriasis: analysis of a multicenter data collection in Italy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1291-1298.	1.4	5
138	Practical indications for the management of non-melanoma skin cancer patients. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 286-294.	0.1	5
139	Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 126-145.	0.8	5
140	Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1585-1592.	1.4	5
141	PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984705.	1.1	4
142	Dermoscopic similarity is an independent predictor of BRAF mutational concordance in multiple melanomas. <i>Experimental Dermatology</i> , 2019, 28, 829-835.	1.4	4
143	Comment on "Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines". <i>European Journal of Cancer</i> , 2020, 131, 100-103.	1.3	4
144	Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia. <i>Dermatology</i> , 2021, 237, 705-711.	0.9	4

#	ARTICLE	IF	CITATIONS
145	Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. Italian Journal of Dermatology and Venereology, 2021, , .	0.1	4
146	5-Aminolaevulinic acid patch photodynamic therapy for the treatment of actinic keratoses: preliminary results from an Italian study in the real-life setting. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 636-641.	0.8	4
147	Occurrence of hidradenitis suppurativa and phrynoderma after bariatric surgery. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1215-1217.	1.3	3
148	Propofolâ€nduced irreversible hair depigmentation: a case report. International Journal of Dermatology, 2017, 56, 676-678.	0.5	3
149	Clinico-dermoscopic features of alopecia areata in patients with psoriasis. JAAD Case Reports, 2018, 4, 665-668.	0.4	3
150	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. Future Oncology, 2020, 16, 1091-1100.	1.1	3
151	Reflectance confocal microscopy and its role in the followâ€up of a topical treatment for lentigo maligna. International Journal of Dermatology, 2021, 60, 196-200.	0.5	3
152	SARS-CoV-2 vaccines and biological treatments: dermatological perspectives. Italian Journal of Dermatology and Venereology, 2021, 156, 118-120.	0.1	3
153	Morpheaâ€like changes in the setting of cancer immunotherapy. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e684-e685.	1.3	3
154	Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy. Patient Preference and Adherence, 2021, Volume 15, 2551-2562.	0.8	3
155	Human leukocyte antigenâ€B*58:01 allele in a familial case of Stevensâ€Johnson syndrome induced by allopurinol. Journal of Dermatology, 2015, 42, 753-754.	0.6	2
156	â€Eternal sunshine of the spotless islandsâ€™: how dermoscopy may influence confocal microscopy when dealing with squamous cells carcinoma simulating basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e277-e280.	1.3	2
157	Sclerosing nevus with pseudomelanomatous features: dermoscopic and confocal aspects. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 525-532.	1.3	2
158	The presence of eccentric hyperpigmentation should raise the suspicion of melanoma. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2802-2808.	1.3	2
159	Treatment monitoring of <sc>5â€fluorouracil</sc> 0.5%/salicylic acid 10% lesionâ€directed therapy for actinic keratosis using dermoscopy and inâ€vivo reflectance confocal microscopy. Dermatologic Therapy, 2020, 33, e13744.	0.8	2
160	Reflectance Confocal Microscopy Applied to Folliculitis Decalvans: Preliminary Results of a Multicenter Study. Skin Appendage Disorders, 2020, 6, 202-206.	0.5	2
161	One case of anetoderma postâ€vitamin K 1 injection in a newborn. International Journal of Dermatology, 2020, 59, e168-e169.	0.5	2
162	Jellyfish Stingâ€”In Vivo Imaging for Diagnosis and Treatment Monitoring. JAMA Dermatology, 2020, 156, 348.	2.0	2

#	ARTICLE	IF	CITATIONS
163	Purple papules during anti-EPD1 immunotherapy for metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 630-632.	0.4	2
164	Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.1	2
165	Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e923-e926.	1.3	2
166	Lentigo maligna: diagnosis and treatment. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 179-189.	0.8	2
167	A case of chronic disseminated lupus erythematosus in a psoriatic patient receiving ustekinumab. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 699-701.	0.8	2
168	Back to work from the lockdown: recommendations from the Italian Society of Dermatology (SDeMaST) and the Italian Forensic Dermatologic Society (SDeLF). Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 381-383.	0.8	2
169	Linear and Bilateral Multinucleated Cell Angiohistiocytoma (MCAH). Journal of Dermatological Case Reports, 2017, 10, 58-61.	1.1	2
170	Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series. Italian Journal of Dermatology and Venereology, 2018, 153, 333-337.	0.1	2
171	Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy. Dermatitis, 2022, 33, e25-e29.	0.8	2
172	Severe and resistant palmar psoriasis successfully treated with risankizumab. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.1	2
173	Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.1	2
174	Use of reflectance confocal microscopy to diagnose occult basal cell carcinoma: 2 case reports. JAAD Case Reports, 2018, 4, 599-601.	0.4	1
175	Response to: Comment on "Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines"™. European Journal of Cancer, 2020, 140, 154-157.	1.3	1
176	The Safety of Radiotherapy in the Treatment of Primary Cutaneous B-Cell Lymphoma: A Multidisciplinary Systematic Review. Frontiers in Oncology, 2020, 10, 1133.	1.3	1
177	Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone family. Familial Cancer, 2022, 21, 347-355.	0.9	1
178	Annular elastolytic giant cell granuloma following herpes zoster infection. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e334-e335.	1.3	0
179	Commentary to Shetty A, Janda M, Fry K et al. Clinical utility of skin cancer and melanoma risk scores for population screening: TRoPICS study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1244-1245.	1.3	0
180	A strange perianal ulcer. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 738-740.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Dermatoscopic and confocal microscopy features of widespread inflammatory linear verrucous epidermal nevus. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.1	0
182	Cold-Induced Urticaria in Children. Skinmed, 2021, 19, 339-348.	0.0	0
183	Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi. Dermatology, 2022, 238, 986-995.	0.9	0